Edgewise Files Pro Forma Financials for $1.55B Sevasemten Sale to Servier
EWTX has more than doubled off its 52-week low of $12.3.
Summary
Edgewise Therapeutics filed pro forma financials for its $1.55B sale of the sevasemten program to Servier, revealing a $1.49B gain, $1.53B in pro forma cash, and a shift to a cardiovascular focus.
Key Events · M&A and Partnerships · EWTX
-
Pro Forma Financials Filed
The 8-K/A provides unaudited pro forma financials for the $1.55B sale of the sevasemten program to Servier, closed July 10, 2026.
-
$1.49B Gain on Sale
The transaction results in an estimated $1.49B pre-tax gain ($1.26B after-tax), calculated as $1.55B upfront cash plus $9.6M net liabilities assumed, less $4.1M assets transferred, $50M transaction costs, and $17.9M deferred for transition services.
-
Balance Sheet Transformation
Pro forma cash and equivalents surge to $1.53B as of March 31, 2026, from $33.2M historically, with total assets of $2.01B and stockholders' equity of $1.75B.
-
Income Tax Impact
The company estimates $225.9M in income taxes payable, as the taxable gain exceeds available net operating loss carryforwards after Section 382 limitations.
Analysis · EWTX · Life Sciences
This amendment delivers the first detailed look at the financial impact of the $1.55 billion sale of Edgewise's muscular dystrophy program to Servier, which closed on July 10. The pro forma statements reveal a massive $1.49 billion pre-tax gain, transforming the balance sheet with $1.53 billion in cash and equivalents and driving pro forma net income to $1.14 billion for 2025. The divestiture also eliminates significant operating expenses, shrinking the quarterly net loss from $49 million to $28 million. However, an estimated $225.9 million in income taxes will come due, and the transition services agreement will keep some costs on the books. This filing confirms the deal's transformative effect, leaving Edgewise as a pure-play cardiovascular company with a fortified cash position.
At the time of this filing, EWTX was trading at $39.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $12.30 to $48.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.